Abbott Laboratories (ABT) Rated Buy as Benchmark Highlights Diagnostics Growth and Global Resilience

Core Insights - Abbott Laboratories (NYSE:ABT) is recognized as one of the top medical device stocks, with Benchmark initiating coverage on October 10, setting a price target of $145 and a Buy rating, highlighting the company's reliable performance in a dynamic global market [1] Group 1: Business Strategy and Market Position - Abbott's business strategy is characterized by its independence from any single treatment, product, or market, which contributes to its resilience [1] - The company is expected to see a resurgence in its Diagnostics business by 2026, driven by a new molecular nucleic acid testing platform for blood screening, despite current challenges from post-pandemic declines in COVID-19 testing and pressures in China [2] Group 2: Investment and Expansion - Benchmark noted Abbott's proactive approach to potential trade disruptions, citing a $500 million investment in new U.S. facilities and expansions planned for the upcoming year, positioning the company favorably for future tariff discussions [3] - Abbott Laboratories is a leading global healthcare company, producing a diverse range of products including branded generic medications, medical devices, diagnostics, and nutritional items [3]